GlassScriptPhysician profile
Arie L Weinstock
NPI 1952371346
$27,190.34
in general payments reported to CMS, 2019-2025
26 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $1,582 · 2021: $2,114 · 2022: $1,818 · 2023: $944 · 2024: $2,645 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,656 · Consulting Fee: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,655.72 |
| Consulting Fee | $1,674.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $16,045.92 | 2019-2021 | |
| Ucb, INC. | $2,685.87 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neuropace, INC. | $2,375.98 | 2019-2024 | |
| Otter Pharmaceuticals, LLC | $1,674.00 | 2024 | Sympazan |
| Zogenix INC. | $1,100.00 | 2020 | |
| Zimmer Biomet Holdings, INC. | $944.34 | 2019-2022 | |
| Biogen, INC. | $322.56 | 2019-2025 | Spinraza |
| Biomarin Pharmaceutical INC. | $217.98 | 2019-2023 | Brineura |
| Neurelis, INC. | $204.63 | 2021-2024 | Valtoco |
| Pyros Pharmaceuticals, INC. | $195.32 | 2024 | Vigpoder |
| Medtronic USA, INC. | $178.27 | 2019 | |
| Sk Life Science, INC. | $176.74 | 2023-2025 | |
| Livanova USA, INC. | $145.42 | 2023-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Alexion Pharmaceuticals, INC. | $144.83 | 2019 | |
| Jazz Pharmaceuticals INC. | $139.19 | 2023-2025 | Epidiolex |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $125.00 | 2025 | |
| Eisai INC. | $125.00 | 2019 | |
| Mallinckrodt Enterprises LLC | $86.95 | 2019 | |
| Biocodex, INC. | $84.74 | 2024 | |
| Acadia Pharmaceuticals INC | $57.32 | 2023-2024 | Daybue |
| Upsher-Smith Laboratories LLC | $55.92 | 2025 | |
| Supernus Pharmaceuticals, INC. | $39.61 | 2021-2022 | |
| Monteris Medical Corporation | $34.06 | 2022 | |
| Travere Therapeutics, INC. | $30.69 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arie Weinstock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.